- New
board member, audit committee chair brings 35 years of accounting
experience, mainly in management
- Prior
worked as CFO, controller in several genomics, health companies
- POAI
to leverage Prior’s new insights, guidance in the financial space
Predictive Oncology Inc. (NASDAQ: POAI), a leader in the
cancer precision-medicine field, announced that Pam Prior, CPA, has been
appointed to the company’s Board of Directors. In addition to holding a seat on
the board, Prior will also chair the company’s audit committee.
Prior, 57, joins POAI’s Board of Directors with 35 years of
experience in accounting, mainly in management as CFO or controller. As the
founder and CEO of Priorities Group Inc., a provider of CFO services to small
and mid-sized businesses, she has served as a CFO to a number of companies,
including Gentris Corp., a private pharmacogenomics company subsequently
purchased by Cancer Genetics Inc. Most recently, Prior was CFO at Schiller
Grounds Care, a privately held lawn and garden equipment manufacturer.
Other previous CFO experience includes working with
companies in the health-industry space such as Global Specimen Solutions, a
privately held technology company for specimen and consent management (later
purchased by Covance), and multimillion-dollar companies in other industries
such as Greatwide Truckload Management, a $300 million subsidiary of a $1
billion privately held logistics company.
“Predictive Oncology is very fortunate to announce that Pam
Prior is joining our Board of Directors,” Predictive Oncology CEO Dr. Carl
Schwartz stated in a news release (http://ibn.fm/hJEDR). “Pam possesses a strong financial
background, including in the genomic and health industry fields. She will chair
our audit committee, providing new insights and guidance to our Board and the
financial departments of the company. I greatly anticipate working with Pam and
experiencing the successful approach she has honed over the years.”
In addition to her background in the health industry, Prior
also has experience serving as controller for several publicly traded companies
and their subsidiaries, including Tasty Baking Company and PCI Services, a part
of publicly held Cardinal Health.
Prior is a licensed CPA in the Commonwealth of Pennsylvania,
with an MBA and a bachelor’s degree from the University of Delaware. She also
serves as treasurer on the boards of two nonprofit organizations: The Crossing
Choir, a professional choir holding two Grammy Awards and seven Grammy
nominations, and A Soldier’s Hands, a grassroots organization dedicated to
delivering care packages to deployed United States military personnel.
As a highly respected and seasoned finance executive with
valuable genomics and health industry experience, Prior joins POAI at a time
when the company has announced a significant milestone in its CancerQuest 2020
initiative. The initiative indicates a progression in its proprietary AI-driven
predictive model of ovarian cancer, which it expects to commercialize in the
first quarter of 2020.
Prior’s engagement in providing new insights and guidance to
the board and POAI’s financial departments will position the company to
capitalize on its cutting-edge technology that offers an unparalleled
predictive tool for pharmaceutical companies and medical researchers, enabling
more effective development of new drugs and supporting clinicians in creating
individualized therapies for their patients.
POAI is bringing precision medicine, or tailored medical
treatment using the individual characteristics of each patient, to the
treatment of cancer. Through its Helomics division, the company leverages its
unique, clinically validated patient derived (PDx) smart tumor profiling
platform to provide oncologists with a roadmap to help individualize therapy.
In addition, the company is leveraging artificial intelligence and its
proprietary database of over 150,000 cancer cases tumors to build AI-driven
models of tumor drug response to improve outcomes for the patients of today and
tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
